Dovato, a combination treatment for HIV, is expected to see its primary patent expire in 2034 [1][2]. This patent is held by ViiV Healthcare [1][3].
When does Dovato's market exclusivity end?
Market exclusivity for Dovato is tied to its patent protection. While the main patent is set to expire in 2034, other forms of intellectual property, such as secondary patents or regulatory exclusivities, could influence the timeline for generic competition. Information on specific secondary patent expirations and their potential impact can be found on resources like DrugPatentWatch.com [1].
What happens when Dovato's patent expires?
Upon patent expiry, generic manufacturers are typically able to produce and market their own versions of Dovato, provided they receive regulatory approval. This is expected to lead to increased competition and potentially lower prices for the medication [4].
Who makes Dovato and its generic versions?
Dovato is developed and marketed by ViiV Healthcare [1][3]. Once patents expire, other pharmaceutical companies may seek to produce generic versions, subject to regulatory approval by agencies like the U.S. Food and Drug Administration (FDA).
Can other HIV medications compete with Dovato?
Dovato's primary advantage is its fixed-dose, single-tablet regimen combining dolutegravir and lamivudine, which simplifies treatment for patients [5]. Other HIV medications, including single-tablet regimens from different manufacturers and separate pills, offer alternative treatment options. Competition exists from other dolutegravir-based regimens and other drug classes.
What are the risks associated with Dovato?
Common side effects reported for Dovato include upper respiratory tract infection and headache [5]. As with any medication, patients should discuss potential risks and side effects with their healthcare providers.
What is the clinical data supporting Dovato?
Dovato has been studied in clinical trials, such as the DOV-DOMO study, which demonstrated its efficacy in maintaining viral suppression in treatment-naïve adults [5]. The drug is indicated for the treatment of HIV-1 infection in adults and adolescents without a history of prior antiretroviral therapy for HIV-1 infection [5].
How does Dovato's patent situation compare to other HIV drugs?
The patent landscape for HIV medications is complex, with many drugs having multiple patents covering different aspects of their formulation, manufacturing, and use. The expiration of patents for other major HIV treatments has previously opened the door for generic competition and price reductions in the market. Information on patent expiry dates for various HIV drugs is available through patent tracking services [1].
What is the pricing of Dovato?
Pricing for prescription medications can vary based on insurance coverage, pharmacy, and geographic location. Following patent expiry and the introduction of generic versions, the cost of Dovato is expected to decrease.
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/search/dovato/86964
[3] https://viivhealthcare.com/en-us/our-medicines/dovato/
[4] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/generic-drugs-how-they-work
[5] https://www.dovato.com/